Krystal Biotech Financial Ratios
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Krystal Biotech ratio analysis
Krystal Biotech earned a net margin of 52.6% in FY 2025, up from 30.7% a year earlier. Return on equity reached 16.8%, meaning Krystal Biotech generated 0.17 dollars of profit for every dollar of shareholders' equity. At the end of FY 2025, KRYS traded at 36.1 times earnings; across the 3 fiscal years shown, its year-end P/E ranged from 36.1 to 318.1, with a median of 52.8.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Krystal Biotech financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 36.10 | 52.78 | 318.10 | — | — | — | — | — | — | — |
| Price / sales | 18.37 | 15.58 | 66.45 | — | — | — | — | — | — | — |
| Price / book | 5.86 | 4.78 | 4.33 | 3.87 | 2.62 | 3.86 | 4.67 | 2.51 | 1.14 | — |
| Operating margin | 41.5% | 22.6% | -216.2% | — | — | — | — | — | — | — |
| Net margin | 52.6% | 30.7% | 21.6% | — | — | — | — | — | — | — |
| Free cash flow margin | 48.5% | 41.0% | -198.4% | — | — | — | — | — | — | — |
| Return on equity (ROE) | 16.8% | 9.4% | 1.4% | -26.8% | -11.7% | -11.0% | -9.4% | -9.6% | -16.0% | -397.9% |
| Return on assets (ROA) | 15.4% | 8.4% | 1.3% | -25.1% | -11.1% | -10.3% | -9.1% | -9.4% | -15.8% | -52.7% |
| Current ratio | 9.95 | 7.28 | 17.76 | 13.30 | 17.18 | 17.80 | 58.88 | 43.39 | 77.99 | 50.44 |
| Revenue growth | 33.9% | 473.0% | — | — | — | — | — | — | — | — |
| EPS growth | 128.0% | 669.2% | — | — | — | — | — | — | — | — |